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The incidence of candidiasis has been steadily 
increasing over the past decade (1). Although 
candiduria is a frequently reported phenomenon 
in hospitalized patients (2-3), its overall clinical 
relevance is still uncertain and the question remains 
whether this event goes beyond mere non- virulent 
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There is a great concern for the increasing incidence of candidiasis in cancer patients following immune-
suppressive, cytostatic or antibiotic treatment. There are cancer patients with repeat asymptomatic 
recovery of candida in the urine in whom the choice of treatment, if any, is still a matter of debate. The 
aim of the study is to test the efficacy and tolerability of a natural anti-fungal phytocompound in patients 
with tumors of the gastrointestinal tract with prior or ongoing candiduria. Thirty-nine patients with 
operated gastrointestinal malignancies (18 still under current chemotherapy) with a history of repeated 
candiduria were enrolled. Eleven patients showed candiduria on enrolment and were treated with K-
712, a natural antifungal phytocompound. Genomic analysis was carried out on blood samples of all 
patients on a monthly basis for 6 months. Within 3 weeks all 11 treated patients had negative cultures 
in the urine (10 patients after 2 weeks), 7 patients remained free of candiduria throughout the study 
period while 4 required a new treatment course. Three patients had positive genomic tests for systemic 
candidiasis and were treated with fluconazole. Eighteen (64%) out of the 28 patients who were free of 
candiduria on enrolment, developed a urinary candida infection during the 6-month follow-up and all 
cases were successfully treated with K-712. Seven (38%) of these cases presented a further recurrence at 
a later stage and all responded to a new course of K-172. No positive genomic tests were observed during 
the follow-up period. These data suggest that a consistent part of patients, mostly with gastrointestinal 
malignancies develop urinary candida infection when following chemotherapy treatment. A therapeutic 
approach with a natural antifungal phytocompound seems a safe and effective measure and a tentative 
prophylactic approach might also be envisaged. 
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ongoing candiduria and no other known infectious 
complications. 
MATERIALS AND METHODS
The study population consisted of thirty-nine subjects 
(male/female: 22/17, mean age: 68 yrs age range: 61-77) 
(Table I). All subjects had a history of surgical resection 
and chemotherapy for gastrointestinal tumor (21 colon 
cancer, 13 gastric cancer, 5 oesophageal cancer) and 
repeat asymptomatic/subclinical candiduria in the last 
year (four or more episodes). Eighteen subjects were 
being treated with chemotherapy while the remaining had 
completed their therapeutic protocol within the previous 
year. Seven had also been subjected to radiotherapy. Ten 
patients had been found to have distant metastasis (11 
liver, 2 lungs, 1 peritoneal, 1 ovary, 1 bone). Twelve 
patients had a history of associated major diseases (4 
myocardial infarct, 2 stroke, 10 diabetes) (Table I). 
Eight patients were underweight, nine were anaemic 
(Hb < 11.0g/dl) and seven patients (all under current 
chemotherapy) were neutropenic (defined if the absolute 
neutrophilic count in the peripheral circulation was <500 
cells/mm3). All patients gave their informed consent at 
entry and were clinically stable without fever or clinical/
laboratory signs of infection. Patients were instructed 
to avoid taking probiotics or any food supplement and 
to inform the investigator if prescribed any antibiotics 
by their referring oncologist. After an overnight fast, 
patients provided a urine sample for bacterial and candida 
infection determination. The success was defined as a 
proven eradication of candida species at the first control 
after having started the treatment,
Assessment of candiduria
The urine samples were spread by calibrated loop 
(0.01 ml) onto Sabouraud dextrose agar plates which were 
supplemented with 100 µg/ml of chloramphenicol. Plates 
were incubated in anaerobiotic condition at 37ºC and read 
within 24 h. The amount of 100 CFU/ml, representing 
a single colony of yeast on a plate was regarded as a 
detection limit. Candida species were identified by 
germ tube formation in fetal calf serum at 37ºC, colony 
morphology on cornmeal agar and sugar fermentation 
and assimilation tests (18). Identification was confirmed 
by API 20C Aux System for yeasts and C. albicans ATCC 
10231 and C. parapsilosis 22019 were used as control.
Genomic analysis of systemic candidiasis
DNA was extracted from blood specimen using a 
lysis buffer containing Iris-HCL. EDIA. sodium dodecyl 
sulphate (SDS), proteinase K. lysozyme and Tween 20 
colonization (4). Nonetheless, there are a number 
of well-defined risk factors and/or predisposing 
conditions which suggest the pathological significance 
of candiduria even when detected in asymptomatic 
patients (5). These are: diabetes mellitus, antibiotic 
or immune suppressive therapy and malignancies 
(6-7). For instance, about 20% of cancer patients are 
found to have fungal lesions in the small and large 
intestine (8). Even if the association between candida 
colonization and cancer has been well documented, 
only recently it was further clarified that, among 
cancer patients, candidiasis is mostly present in 
those with solid tumors of the gastrointestinal tract, 
especially if metastasis is present (9). Nonetheless, 
while overt candida infection with pyrexia and/or 
severe neutropenia meets a general consensus for 
the need of  medical treatment, the medical conduct 
still remains to be defined in asymptomatic patients 
without major derangements of the immune system. 
A further caution in such cases is represented 
by the possible side effects of pharmacological 
antifungal treatment and drug  resistance (10-11). 
Indeed, several chemically synthesized antifungal 
molecules have proven their efficacy in clinical 
practice but also pose the threat of toxic effects and 
opportunistic bacterial overgrowth (12). During the 
past decade, fluconazole has been mainly used in 
high-risk populations, such as neutropenic patients 
and, together with its unquestionable benefits 
against systemic candidiasis, this has also led to 
a selection-driven shift from highly susceptible 
to less susceptible Candida species. We have 
recently shown that a phytocompound containing 
polygodyal and anethole could significantly inhibit 
candida colonization of the gut as well its systemic 
translocation in experimental animals (13-14). 
Polygodial is a component of Pseudowintera colorata 
and it has long been used as a phytotherapeutic agent 
for its antibacterial and antifungal properties (15). 
In recent years an anethole/polygodial compound 
has been used clinically (16) since it has been found 
that anethole, a natural compound isolated from 
Pimpinella anisum, enables a more than 30-fold 
increase in the antifungal activity of polygodial 
against Candida Albicans in in vitro studies (17). 
The aim of the present study is to test the efficacy 
and tolerability of this phytocompound in patients 
with tumors of the gastrointestinal tract with prior or 
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(Sigma Chemicals. USA). Equal quantities (100 L) of 
the sample and the lysis buffer were mixed and incubated 
for 2 h at 55°C. Proteinase K was then inactivated, by 
heating the mixture to 95°C for 10 minutes. DNA was 
then extracted by the phenol-chloroform method and 
precipitated by using isopropanol. Briefly, 500 µl of 
saturated phenol was added with 250 µl of a chloroform/
isoamyl alcohol mixture in the ratio 24:1 to the above 
solution and centrifuged at 14000 rpm for 15 minutes 
and maintained at 4°C. The DNA was then precipitated 
from the aqueous phase with isopropanol. The DNA was 
then dissolved in 15 µL of Tris-EDTA buffer to serve as 
a template. 
As for DNA Amplification, a 197 bp fragment of 
the 18S rRNA gene, which is common in all medically 
relevant fungi was amplified. Primers RIBIF - AGC 
TCT TTC TTG ATT TTG TGG and NS-6 - GCA TCA 
CAG ACC TGT TAT TGC C’TC were used to yield 
appropriate amplification. The reaction was performed 
in a total volume of 50 µL with 10 mM TAPS, 1.5 mM 
MgCl2, 50 mM KC1, 1 mM of each dNTP, 0.02 µg/mL 
of each primer, 2.5U of Taq polymerase and 5 µL of the 
DNA template which had been preheated to 95°C for 2 
minutes. The amplification reaction consisted in an initial 
denaturation cycle of 94°C for 5 min followed by 30 
cycles of 94°C for 1 min, 55°C for 2 min, 72°C for 2 min 
and a final extension step of 72°C for 7 min. The amplified 
product was subjected to electrophoresis on a 2% agarose 
gel containing 0.5 µm/mL of ethidium bromide and the 
product size was checked each time as compared with 
Hinf I digested pBR-322 marker.
Treatment protocol
In the case of positive candida detection in the urine 
but in the absence of fever or systemic signs of infection, 
patients were immediately supplemented with 1 tablet 
three times a day for 3 weeks of a polygodial/anethole 
phytocompound  (K-712, supplied by Named srl, 
Lesmo, Italy; the 100 mg composition is: Pseudowintera 
colorata 50 mg, Pimpinella anisum 41.5 mg, lactobacillus 
acidophilus 2.9 mg and vitamin C 5.6 mg). Urine cultures 
were carried out on a weekly rate till eradication of the 
fungi and thereafter monthly for 6 months. Treatment was 
stopped and a new clinical evaluation was required in case 
of a febrile illness defined as more than two successive oral 
readings of greater than or equal to 38°C for the 24-hour 
period prior to administration of a systemic antifungal 
therapy. The diagnosis of systemic candidaemia was 
based on the isolation of the yeast from one or more blood 
culture sets (aerobic and/or anaerobic bottles) collected 
from febrile patients. Blood cultures were performed using 
the automated blood culture system ( Beckton Dickinson, 
USA). Presumptive identification was made by the use 
of germ tube reaction, colony morphology and colour 
reaction on chrom agar. Identification to species level was 
done by the commercial identification system API 20C 
(Analytic Products, NY, USA). Concomitantly, genomic 
analysis was performed in all patients on a monthly basis 
all during the study, irrespective of the clinical evidence 
of infection.
RESULTS
At the start of the study period, eleven patients 
(28.9% of the entire study group, male/female: 
4/7) showed evidence of candiduria without any 
remarkable subjective changes in their clinical 
status. The demographic characteristics of positive 
patients at entry were as follows: eight (72 %) of 
the 11 patients were undergoing a chemotherapeutic 
treatment, six (54%) were underweight, five (45%) 
had distant metastasis, five (45%) were neutropenic 
and three (27%) were diabetic. As shown in Fig. 1, 
63% of detected candida at entry (7 patients) was 
diagnosed as Candida albicans while the remaining 
were non-albicans strains. Genomic analysis 
revealed that 3 patients had systemic spread of 
fungal infection. One patient also showed a positive 
urine culture for candida, while the other two had 
no candiduria. All these patients were treated with 
fluconazole. Besides the one patient with candiduria 
who also developed systemic infection, of the other 
patients with candiduria at entry who were treated 
with K-712, 7 patients (63%) showed a repeat 
episode (including one case with definite symptoms 
but whose sample could not be examined due to 
technical problems). Such patients were successfully 
treated within 2 weeks with a new course of treatment 
containing the same phytocompound (Fig. 2). The 
same occurred with another 4 (36%) recurrent cases. 
The remaining 3 patients maintained a candida-free 
condition throughout a 6-month observation period. 
Eighteen (64%) of the 28 patients who were free 
of candiduria at entry, developed urinary candida 
infection during the 6-month follow-up and all cases 
were successfully treated with K-712. Six (33%) of 
these cases presented with further recurrence at a 
later stage (1-4 months afterwards) and all responded 
to a new course of K-172. No positive genomic tests 
for systemic candidiasis were found during the 
observation period. No side effects of treatment with 
phytocompound were reported. During the follow-
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of diabetic patients might have precluded from a 
detailed analysis of this relevant further risk factor 
for candidiasis. Moreover, although a statistical 
analysis could not be applied due to the limited 
number of cases, malnourished patients constituted 
63% (12/22) of patients presenting their first episode 
of candiduria during the study and 70% (12/17) of 
all recurrences after a successful eradication .
DISCUSSION
The incidence of hospital urinary tract infections 
has remarkably increased in the two past decades due 
to a number of predisposing or risk factors associated 
with the onset of candiduria such as the use of 
indwelling urinary catheters, antibiotic treatments, 
diabetes mellitus, immunosuppressive therapy, 
prolonged hospital stay, female sex and advanced 
up period 9 patients received antibiotic treatment (6 
for pulmonary infection, 1 for suppurative arthritis, 1 
for diverticulitis, 1 for urinary bacterial infection and 
1 for suppurative post-traumatic skin lesion). Three 
of these patients were on K-712 treatment (1 with 
pulmonary infection, 1 with diverticulitis and 1 with 
suppurative skin lesion) which was maintained and no 
fungal overgrowth following the antibiotic treatment 
occurred at urinary culture and genomic blood 
analysis. Overall, Candida albicans accounted for 
33 (70%) of all 47 positive candiduria tests while the 
remaining were due to Candida glabrata (12 cases, 
25%) and Candida parapsilosis (2 cases, 4.2%). In 
all 11 episodes of repeat candiduria episodes after 
first treatment with K-172, there was no shift of 
candida strain. Overall, there did not appear to be 
any significant difference between diabetic and 
non-diabetic patients, although the limited number 
Table I. Demographic and clinical characteristics of cancer patientsand associated diseases.
Male: female  22: 17 
Mean age (age range) 68 (61-77) 
Colon cancer (non resected) 21 (1) 
Without distant metastasis 15 
With distant metastasis 6 
Gastric cancer 13 
Without distant metastasis 10 
With distant metastasis 3 
Oesophageal cancer 5
Without distant metastasis 4 
With distant metastasis 1 
Chemotherapy (currently) 39 (18) 
Additional radiotherapy 7 
Distant metastasis localization 
Liver 11 
Lungs 2 
Peritoneal 1 
Ovary 1 
bone 1 
Associated Diseases 
Myocardial infarction 4 
stroke 2 
diabetes 10 
malnourishment 16 
anemia  9 
neutropenia 7 (all under current chemotherapy) 
O
Table I. Demographic and clinical characteristics of cancer patientsand associated diseases.
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Fig. 1. Candida infection: microbiological findings at the entry and in the overall population. 
Percentage distribution of different Candida species in patients who were positive for candiduria 
at entry (11 patients) and in the whole population (39 patients) during treatment and follow-up 
period.  
Fig. 1. Candida infection: microbiological findings at the entry and in the overall population. Percentage distribution of 
different Candida species in patients who were positive for candiduria at entry (11 patients) and in the whole population 
(39 patients) during treatment and follow-up period. 
Fig. 2. Treatment schedule and follow-up of all patients.
Fig. 2. Treatment schedule and follow-up of all patients.
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age (5). Understandably, cancer patients are the most 
exposed subjects to such clinical complication and 
Candida is one of the five most frequently isolated 
microbes from blood cultures. Indeed, Candida 
species are by far the most common cause of fungal 
infections and they produce infections that range 
from non-life threatening mucocutaneous illnesses 
to invasive processes that may eventually involve 
any body organ (19). 
Although previous studies suggest that 
asymptomatic candiduria might be uneventful and 
not require local or systemic antifungal therapy (20), 
even in compromised patients, this opportunistic 
overgrowth should never be dismissed, since this 
condition may unexpectedly trigger a systemic or 
invasive candidiasis (21). Accordingly, Ahmad et 
al. (22) observed that two Candida albicans isolates 
from overt candidemia patients were similar to those 
from their urine and oral isolates, when analyzed 
by random amplification of polymorphic DNA, 
thus supporting the view that prior colonization 
is a strong risk factor. In this context, current 
cytotoxic and immunosuppressive therapies are 
limited by the inadequate availability of non-toxic 
antifungal molecules. In view of minimizing further 
interference with the existing biological ecosystem 
secondary to the use of chemically synthesized 
antifungal molecules (23-25), a number of different 
approaches, such as the use of phytochemicals, are 
under investigation (26-27). In the present study 
we used a natural phytotherapeutic agent based 
on anethole/polygodial, which we have previously 
shown to significantly inhibit Candida adhesiveness 
to duodenal mucosa as well as limiting its luminal 
translocation while being devoid of toxic effects in 
experimental studies (13-14, 28).
Despite the increased rates in life-threatening 
invasive yeast infection, many of these infections 
either remain undetected or are detected late in 
clinical practice since the blood concentration of 
fungal cells is generally low (29) and patients with 
fungemia may often present with minimal clinical 
manifestations. Already 15 years ago, Berenguer 
et al. (30) showed that approximately one-half of 
patients with serious invasive Candida infections 
may repeatedly have negative blood cultures. In our 
study, we selected a population of cancer patients 
who were theoretically more liable to undergo 
Candida infection, due to their prior repeated 
exposure. Given the subtle condition, to the best of 
our knowledge, there is no definite data of cancer 
patients developing candiduria and this may be the 
first observation. Our data suggest that in such a 
situation, there was indeed a significant percentage 
(46%) with ongoing asymptomatic candiduria 
which was successfully treated with the natural 
K-712 intervention. Interestingly, none of these 
patients developed a relapse candiduria episode 
during treatment nor any superimposing urinary 
bacterial infection. To foster this data, it appeared 
that those who underwent an antibiotic treatment 
for an infection located elsewhere in the body, did 
not develop any fungal overgrowth, although the 
limitation of blood concentration testing does not 
allow to make any concrete inference. One patient 
with candiduria following the K-172 treatment 
showed genomic signs of systemic infection which 
was promptly treated with fluconazole. It is not 
possible to ascertain whether the systemic spread 
originated in his urinary tract or elsewhere, and 
a strict surveillance of fungemia remains a gold 
standard in this specific clinical setting. Interestingly, 
candiduria appeared to be more frequent in female 
patients (72%) than in males (p < 0.05). The higher 
incidence in females may reflect vaginal candidiasis 
since it is possible that yeasts may ascend from the 
genital tract to the urinary tract, as already suggested 
by Febré et al. (31). This author found that five of 
eight patients with positive vaginal secretions had 
the same yeast species in their urine. The vaginal 
microflora involvement might be a plausible 
explanation also in our study although we did not 
obtain vaginal samples to be tested. Over 40% of 
our candiduria patients were underweight and our 
previous experimental findings (13) had stressed 
the importance of nutritional status in maintaining 
host defence mechanisms against fungal invasion. 
Furthermore, impaired macrophage responses to 
Candida have also been observed in underweight 
patients by other authors (31). In particular, the 
kidneys seemed the most vulnerable extra-intestinal 
organ and have been reported to be particularly 
susceptible to Candida albicans. In fact, renal 
failure represents the major cause of death in 
systemic candidiasis, probably because of the lack of 
activation of NF-κB, which promotes the production 
F. MAROTTA ET AL.
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of anticandidal proinflammatory cytokines (33).  
While candiduria surveillance should be routinely 
performed in hospital patients to help reduce 
nosocomial infections, as well as in compromised 
outpatients, and a prompt antifungal drug should be 
employed in positive cases, the present data suggest 
that a natural antifungal compound may be an 
amenable therapeutic strategy in asymptomatic and 
subclinical cases of candiduria with a potential for 
prophylactic use. Longer studies are awaited to test 
the efficacy of this phytocompound in maintaining 
a Candida-free status in these patients as well as the 
possible role of the mild estrogenic-like activity of 
anethole (34). Moreover, the concomitant existence 
of vaginosis cannot be excluded nor can the possible 
synergistic effect played by probiotic components of 
the polyphytocompound. 
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